Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP12 | P39900 | 1/20 | 0.65 |
| ▸ | PARP1 | P09874 | 3/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 4/20 | 0.54 |
| ▸ | NR3C2 | P08235 | 4/20 | 0.52 |
| ▸ | PKM | P14618 | 2/20 | 0.51 |
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | BRAF | P15056 | 1/20 | 0.47 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.47 |
| ▸ | PGR | P06401 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.47 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8006749 | 0.86 | MMP12 (0.51) | MMP12PARP1ALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL30799148 | 0.86 | MMP12 (0.51) | MMP12PARP1ALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL30343101 | 0.79 | MMP12 (0.65) | MMP12PARP1ALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL279594 | 0.79 | MMP12 (1.00) | MMP12PARP1ALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL30015279 | 0.79 | MMP12 (0.65) | MMP12PARP1ALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL861110 | 0.79 | MMP12 (0.65) | MMP12PARP1ALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL707058 | 0.79 | MMP12 (0.65) | MMP12PARP1ALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL277585 | 0.79 | MMP12 (0.65) | MMP12PARP1ALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL302933 | 0.79 | MMP12 (0.65) | MMP12PARP1ALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL4137452 | 0.79 | MMP12 (0.65) | MMP12PARP1ALDH1A1KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017049409-A1 | COMPOSITIONS FOR PROMOTING READTHROUGH OF PREMATURE TERMINATION CODONS, AND METHODS OF USING THE SAME | THE CENTRE FOR DRUG RESEARCH AND DEVELOPMENT (CA) | 2017-03-30 | — | — | WO | disclosed |
| EP-2905283-B1 | Oxazolidinone antibiotics | ACTELION PHARMACEUTICALS LTD (CH) | 2016-12-14 | — | — | EP | disclosed |
| US-9505750-B2 | 5-aminocyclylmethyl-oxazolidin-2-one derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2016-11-29 | — | — | US | disclosed |
| EP-2245028-B1 | 5-AMINOCYCLYLMETHYL-OXAZOLIDIN-2-ONE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2012-02-22 | — | — | EP | disclosed |
| US-20110003789-A1 | 5-AMINOCYCLYLMETHYL-OXAZOLIDIN-2-ONE DERIVATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2011-01-06 | — | — | US | disclosed |
| EP-2245028-A1 | 5-AMINOCYCLYLMETHYL-OXAZOLIDIN-2-ONE DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2010-11-03 | — | — | EP | disclosed |
| WO-2009077989-A1 | 5-AMINOCYCLYLMETHYL-OXAZOLIDIN-2-ONE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2009-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110003789-A1 | 5-AMINOCYCLYLMETHYL-OXAZOLIDIN-2-ONE DERIVATIVES | CNKSR1, KCNH1, CBR3 | MMP12 3915/4885PARP1 1013/4885ALDH1A1 2633/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.